How Early-Stage Pharma Meets Big-Pharma Compliance Standards
I've been selling software for a long time, and these days most of my conversations are with early-stage and mid-sized pharmaceutical companies. ...
Investigator-Initiated Studies Are Up 63% Since 2020
Somewhere in your organization right now, a new investigator-initiated study proposal is sitting in someone's inbox, waiting to be logged, routed, ...
The 4 Pillars of a Governed AI Framework for Life Sciences
In the executive forums where AI leaders compare notes, the conversation has shifted. A year ago it was about what AI agents could do. Now it is ...
How to Automate the IIS Review Process
An investigator just submitted a promising IIS concept in a therapeutic area your organization cares about. What happens to it in the next 90 days ...
No-Login External Collaboration for Publication Management
What do Medical Affairs teams gain when external authors and reviewers are brought into one secure, auditable workflow? The email arrives with the ...
The AI Medical Affairs Hasn't Imagined Yet: Workflows, Not Chatbots
Drawing on the 2026 AI in Medical Affairs Industry Benchmark Survey and a senior leadership roundtable convened at MAPS Americas 2026.
Process Debt in IIS Approvals: Why Medical Affairs Needs Control
Medical Affairs just revised your IIS review protocols. Perhaps oncology studies now need a different review structure. Maybe compliance thresholds ...
Plain Language Summaries: How AI Helps Medical Affairs Scale
Learn how Medical Affairs teams using governed AI tools are able to meet increasing plain language summary (PLS) expectations without scaling budgets.
Shadow AI in Life Sciences: The Compliance Gap Nobody Talks About
Why ungoverned AI tools are filling the gaps your workflow platform left behind.
